Subtopic Deep Dive

Immunohistochemical Classification of Histiocytoses
Research Guide

What is Immunohistochemical Classification of Histiocytoses?

Immunohistochemical classification of histiocytoses uses marker panels like CD1a, langerin, CD68, and factor XIIIa to assign lineage and distinguish entities such as LCH, ECD, and Rosai-Dorfman per WHO 2016/2022 guidelines.

Researchers validate IHC panels for precise nosology in histiocytic disorders. Key markers differentiate Langerhans-related (CD1a+, langerin+) from non-Langerhans types (CD68+, factor XIIIa+). Over 10 papers from 2015-2023 detail marker profiles and algorithmic approaches.

15
Curated Papers
3
Key Challenges

Why It Matters

Precise IHC classification guides targeted therapies like MAPK inhibitors in ECD and trial eligibility (Goyal et al., 2020; 367 citations). It distinguishes ALK-positive histiocytosis for fusion-targeted treatments (Chang et al., 2018; 127 citations). Accurate nosology reduces misdiagnosis in rare neoplasms, improving outcomes (Go et al., 2021; 67 citations).

Key Research Challenges

Marker Overlap in Entities

CD68 positivity spans multiple histiocytoses, complicating LCH vs. ECD distinction. Factor XIIIa aids non-Langerhans but overlaps with sarcomas (Massoth et al., 2021). Algorithmic panels require validation across pediatric cases (Hélias-Rodzewicz et al., 2023).

Molecular-IHC Integration

Recurrent KRAS/MAP2K1 mutations in Rosai-Dorfman demand combined IHC-molecular workflows (Garcés et al., 2017; 277 citations). MAPK alterations in ECD challenge pure IHC reliance (Goyal et al., 2020). Pediatric spectra add complexity (Hélias-Rodzewicz et al., 2023).

Rare Subtype Validation

ALK fusions in histiocytosis need KIF5B-ALK IHC confirmation, but panels lack standardization (Chang et al., 2018). Veterinary models highlight IHC consistency issues (Thongtharb et al., 2015). NCCN guidelines stress multi-marker needs (Go et al., 2021).

Essential Papers

1.

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Gaurav Goyal, Mark Heaney, Matthew Collin et al. · 2020 · Blood · 367 citations

Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) pathway mu...

2.

Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease

Sofía Garcés, L. Jeffrey Medeiros, Keyur P. Patel et al. · 2017 · Modern Pathology · 277 citations

3.

ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion

Kenneth Tou En Chang, Amos Zhi En Tay, Chik Hong Kuick et al. · 2018 · Modern Pathology · 127 citations

4.

Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Ronald S. Go, Eric D. Jacobsen, Robert A. Baiocchi et al. · 2021 · Journal of the National Comprehensive Cancer Network · 67 citations

Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly ...

5.

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma

Lucas R. Massoth, Yin P. Hung, Judith A. Ferry et al. · 2021 · The Oncologist · 53 citations

Abstract Background Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from monocytic or dendritic cell lineage. Whereas the genomic features for Langerhans cell histioc...

6.

Molecular and clinicopathologic characterization of pediatric histiocytoses

Zofia Hélias‐Rodzewicz, Jean Donadieu, Nathalie Terrones et al. · 2023 · American Journal of Hematology · 42 citations

Abstract The spectrum of somatic mutations in pediatric histiocytoses and their clinical implications are not fully characterized, especially for non‐Langerhans cell histiocytosis (‐LCH) subtypes. ...

7.

MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis

Huan Liu, Andrew R. Osterburg, Jennifer L. Flury et al. · 2020 · JCI Insight · 42 citations

Pulmonary Langerhans cell histiocytosis (PLCH) is a rare smoking-related lung disease characterized by dendritic cell (DC) accumulation, bronchiolocentric nodule formation, and cystic lung remodeli...

Reading Guide

Foundational Papers

Start with Goyal et al. (2020) for ECD IHC consensus and Garcés et al. (2017) for Rosai-Dorfman markers, as they establish neoplastic frameworks cited 367+277 times.

Recent Advances

Study Hélias-Rodzewicz et al. (2023) for pediatric spectra and Massoth et al. (2021) for sarcoma distinctions, reflecting 2021-2023 genomic-IHC advances.

Core Methods

Core techniques: IHC panels (CD1a, CD68, langerin, factor XIIIa); algorithmic lineage assignment; mutation-IHC correlation (MAPK, KRAS, ALK fusions).

How PapersFlow Helps You Research Immunohistochemical Classification of Histiocytoses

Discover & Search

Research Agent uses searchPapers('immunohistochemical markers ECD LCH') to find Goyal et al. (2020; 367 citations), then citationGraph reveals Garcés et al. (2017) on KRAS mutations; exaSearch uncovers pediatric IHC (Hélias-Rodzewicz et al., 2023); findSimilarPapers expands to ALK histiocytosis (Chang et al., 2018).

Analyze & Verify

Analysis Agent runs readPaperContent on Goyal et al. (2020) to extract CD1a/langerin profiles, verifies claims with CoVe against WHO guidelines, and uses runPythonAnalysis for marker co-expression stats (pandas heatmap of CD68+ cases); GRADE scores evidence as high for ECD consensus.

Synthesize & Write

Synthesis Agent detects gaps in pediatric non-LCH IHC via contradiction flagging across Hélias-Rodzewicz (2023) and Goyal (2020); Writing Agent applies latexEditText for marker table, latexSyncCitations for 10-paper bibliography, latexCompile for review draft, and exportMermaid for classification flowchart.

Use Cases

"Extract CD68 and factor XIIIa expression data from histiocytosis papers for Python stats."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis(pandas crosstab on marker data from Goyal 2020, Massoth 2021) → matplotlib sensitivity plot output.

"Draft LaTeX table comparing IHC panels for LCH vs ECD."

Synthesis Agent → gap detection → Writing Agent → latexEditText(marker panel) → latexSyncCitations(Garcés 2017, Chang 2018) → latexCompile → PDF table with citations.

"Find code for IHC image analysis in histiocytic sarcoma papers."

Research Agent → paperExtractUrls(Thongtharb 2015) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on segmentation code → quantitative marker density report.

Automated Workflows

Deep Research workflow scans 50+ histiocytosis papers via searchPapers → citationGraph → structured IHC marker report with GRADE scores. DeepScan applies 7-step CoVe to validate ECD panels from Goyal (2020) against pediatric data (Hélias-Rodzewicz 2023). Theorizer generates algorithmic classifier hypotheses from MAPK/IHC overlaps in Garcés (2017) and Chang (2018).

Frequently Asked Questions

What defines immunohistochemical classification of histiocytoses?

It employs markers like CD1a (LCH), langerin (Langerhans), CD68 (macrophage), and factor XIIIa (interdigitating) to classify per WHO guidelines.

What are core IHC methods?

Multi-marker panels distinguish LCH (CD1a+/langerin+) from ECD/Rosai-Dorfman (CD68+/CD1a-); algorithms integrate mutations (Goyal et al., 2020).

What are key papers?

Goyal et al. (2020; Blood; 367 citations) on ECD consensus; Garcés et al. (2017; 277 citations) on Rosai-Dorfman mutations; Chang et al. (2018; 127 citations) on ALK histiocytosis.

What open problems exist?

Standardizing panels for ALK+ and pediatric cases; integrating TMB/IHC for immunotherapy (Goyal et al., 2019); rare sarcoma overlaps (Massoth et al., 2021).

Research Histiocytic Disorders and Treatments with AI

PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:

See how researchers in Health & Medicine use PapersFlow

Field-specific workflows, example queries, and use cases.

Health & Medicine Guide

Start Researching Immunohistochemical Classification of Histiocytoses with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.

See how PapersFlow works for Medicine researchers